Literature DB >> 35554652

Comparison of a preoperative MR-based recurrence risk score versus the postoperative score and four clinical staging systems in hepatocellular carcinoma: a retrospective cohort study.

Hong Wei1, Hanyu Jiang1, Yun Qin1, Yuanan Wu2, Jeong Min Lee3, Fang Yuan1, Tianying Zheng1, Ting Duan1, Zhen Zhang1, Yali Qu1, Jie Chen1, Yuntian Chen1, Zheng Ye1, Shan Yao1, Lin Zhang1, Ting Yang1, Bin Song4,5.   

Abstract

OBJECTIVES: To establish a risk score integrating preoperative gadoxetic acid-enhanced magnetic resonance imaging (EOB-MRI) and clinical parameters to predict recurrence after hepatectomy for patients with hepatocellular carcinoma (HCC) and to compare its performance with that of a postoperative score and four clinical staging systems.
METHODS: Consecutive patients with surgically confirmed HCC who underwent preoperative EOB-MRI between July 2015 and November 2020 were retrospectively included. Two recurrence risk scores, one incorporating only preoperative variables and the other incorporating all preoperative and postoperative variables, were constructed via Cox regression models.
RESULTS: A total of 214 patients (derivation set, n = 150; test set, n = 64) were included. Six preoperative variables, namely tumor number, infiltrative appearance, corona enhancement, alpha-fetoprotein (AFP) level, aspartate aminotransferase (AST) level, and sex, were independently associated with recurrence. After adding postoperative features, microvascular invasion and tumor differentiation were additional significant variables in lieu of corona enhancement and AFP level. Using the above variables, the preoperative score achieved a C-index of 0.741 on the test set, which was comparable with that of the postoperative score (0.729; p = 0.235). The preoperative score yielded a larger time-dependent area under the receiver operating characteristic curve at 1 year (0.844) than three existing systems (0.734-0.742; p < 0.05 for all). Furthermore, the preoperative score stratified patients into two prognostically distinct risk strata with low and high risks of recurrence (p < 0.001).
CONCLUSION: The preoperative score integrating EOB-MRI features, AFP and AST levels, and sex improves recurrence risk estimation in HCC. KEY POINTS: • The preoperative risk score incorporating three EOB-MRI findings, AFP and AST levels, and sex achieved comparable performance with that of the postoperative score for predicting recurrence after hepatectomy in patients with HCC. • Two risk strata with low and high risks of recurrence were obtained based on the preoperative score. • The preoperative score may help tailor pretreatment decision-making and facilitate candidate selection for adjuvant clinical trials.
© 2022. The Author(s).

Entities:  

Keywords:  Carcinoma, hepatocellular; Gadolinium ethoxybenzyl DTPA; Hepatectomy; Magnetic resonance imaging; Recurrence

Year:  2022        PMID: 35554652     DOI: 10.1007/s00330-022-08811-6

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  43 in total

1.  New advances in precision medicine for hepatocellular carcinoma recurrence prediction and treatment.

Authors:  Silvia Vilarinho; Diego F Calvisi
Journal:  Hepatology       Date:  2014-10-24       Impact factor: 17.425

2.  Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases.

Authors:  Jorge A Marrero; Laura M Kulik; Claude B Sirlin; Andrew X Zhu; Richard S Finn; Michael M Abecassis; Lewis R Roberts; Julie K Heimbach
Journal:  Hepatology       Date:  2018-08       Impact factor: 17.425

3.  The role of hepatic resection in the treatment of hepatocellular cancer.

Authors:  Sasan Roayaie; Ghalib Jibara; Parissa Tabrizian; Joong-Won Park; Jijin Yang; Lunan Yan; Myron Schwartz; Guohong Han; Francesco Izzo; Mishan Chen; Jean-Frédéric Blanc; Philip Johnson; Masatoshi Kudo; Lewis R Roberts; Morris Sherman
Journal:  Hepatology       Date:  2015-03-20       Impact factor: 17.425

4.  Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma.

Authors:  Thomas Yau; Vikki Y F Tang; Tzy-Jyun Yao; Sheung-Tat Fan; Chung-Mau Lo; Ronnie T P Poon
Journal:  Gastroenterology       Date:  2014-02-25       Impact factor: 22.682

5.  Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO.

Authors:  L-T Chen; E Martinelli; A-L Cheng; G Pentheroudakis; S Qin; G S Bhattacharyya; M Ikeda; H-Y Lim; G F Ho; S P Choo; Z Ren; H Malhotra; M Ueno; B-Y Ryoo; T C Kiang; D Tai; A Vogel; A Cervantes; S-N Lu; C-J Yen; Y-H Huang; S-C Chen; C Hsu; Y-C Shen; J Tabernero; Y Yen; C-H Hsu; T Yoshino; J-Y Douillard
Journal:  Ann Oncol       Date:  2019-12-20       Impact factor: 32.976

6.  Hepatic resection compared to chemoembolization in intermediate- to advanced-stage hepatocellular carcinoma: A meta-analysis of high-quality studies.

Authors:  Myung Han Hyun; Young-Sun Lee; Ji Hoon Kim; Chan Uk Lee; Young Kul Jung; Yeon Seok Seo; Hyung Joon Yim; Jong Eun Yeon; Kwan Soo Byun
Journal:  Hepatology       Date:  2018-05-21       Impact factor: 17.425

Review 7.  JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan.

Authors:  Masatoshi Kudo; Osamu Matsui; Namiki Izumi; Hiroko Iijima; Masumi Kadoya; Yasuharu Imai; Takuji Okusaka; Shiro Miyayama; Kaoru Tsuchiya; Kazuomi Ueshima; Atsushi Hiraoka; Masafumi Ikeda; Sadahisa Ogasawara; Tatsuya Yamashita; Tetsuya Minami; Koichiro Yamakado
Journal:  Liver Cancer       Date:  2014-10       Impact factor: 11.740

8.  Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes.

Authors:  Shimul A Shah; Sean P Cleary; Alice C Wei; Ilun Yang; Bryce R Taylor; Alan W Hemming; Bernard Langer; David R Grant; Paul D Greig; Steven Gallinger
Journal:  Surgery       Date:  2006-11-01       Impact factor: 3.982

9.  Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition).

Authors:  Jian Zhou; Huichuan Sun; Zheng Wang; Wenming Cong; Jianhua Wang; Mengsu Zeng; Weiping Zhou; Ping Bie; Lianxin Liu; Tianfu Wen; Guohong Han; Maoqiang Wang; Ruibao Liu; Ligong Lu; Zhengang Ren; Minshan Chen; Zhaochong Zeng; Ping Liang; Changhong Liang; Min Chen; Fuhua Yan; Wenping Wang; Yuan Ji; Jingping Yun; Dingfang Cai; Yongjun Chen; Wenwu Cheng; Shuqun Cheng; Chaoliu Dai; Wenzhi Guo; Baojin Hua; Xiaowu Huang; Weidong Jia; Yaming Li; Yexiong Li; Jun Liang; Tianshu Liu; Guoyue Lv; Yilei Mao; Tao Peng; Weixin Ren; Hongcheng Shi; Guoming Shi; Kaishan Tao; Wentao Wang; Xiaoying Wang; Zhiming Wang; Bangde Xiang; Baocai Xing; Jianming Xu; Jiamei Yang; Jianyong Yang; Yefa Yang; Yunke Yang; Shenglong Ye; Zhengyu Yin; Bixiang Zhang; Boheng Zhang; Leida Zhang; Shuijun Zhang; Ti Zhang; Yongfu Zhao; Honggang Zheng; Jiye Zhu; Kangshun Zhu; Rong Liu; Yinghong Shi; Yongsheng Xiao; Zhi Dai; Gaojun Teng; Jianqiang Cai; Weilin Wang; Xiujun Cai; Qiang Li; Feng Shen; Shukui Qin; Jiahong Dong; Jia Fan
Journal:  Liver Cancer       Date:  2020-11-11       Impact factor: 11.740

Review 10.  A global view of hepatocellular carcinoma: trends, risk, prevention and management.

Authors:  Ju Dong Yang; Pierre Hainaut; Gregory J Gores; Amina Amadou; Amelie Plymoth; Lewis R Roberts
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-08-22       Impact factor: 73.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.